Galectin Therapeutics Company Profile (NASDAQ:GALT)

About Galectin Therapeutics

Galectin Therapeutics logoGalectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GALT
  • CUSIP:
Key Metrics:
  • Previous Close: $1.13
  • 50 Day Moving Average: $1.88
  • 200 Day Moving Average: $1.60
  • 52-Week Range: $1.08 - $3.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.04
  • P/E Growth: 0.00
  • Market Cap: $33.09M
  • Outstanding Shares: 29,280,000
  • Beta: 1.33
Profitability:
  • Return on Equity: -188.29%
  • Return on Assets: -102.90%
Debt:
  • Current Ratio: 5.02%
  • Quick Ratio: 5.02%
Additional Links:
Companies Related to Galectin Therapeutics:

Analyst Ratings

Consensus Ratings for Galectin Therapeutics (NASDAQ:GALT) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $4.75 (320.35% upside)

Analysts' Ratings History for Galectin Therapeutics (NASDAQ:GALT)
Show:
DateFirmActionRatingPrice TargetDetails
9/29/2016HC WainwrightDowngradeBuy -> Neutral$8.00 -> $1.50View Rating Details
9/28/2016Roth CapitalReiterated RatingBuy -> Sell$3.00 -> $0.75View Rating Details
8/26/2016FBR & CoReiterated RatingBuyView Rating Details
8/12/2015MLV & Co.Reiterated RatingBuy$16.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Galectin Therapeutics (NASDAQ:GALT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q2($0.24)($0.20)ViewN/AView Earnings Details
5/10/2016Q1($0.17)($0.24)ViewN/AView Earnings Details
3/15/2016Q415($0.22)($0.19)ViewListenView Earnings Details
11/9/2015Q3($0.20)($0.26)ViewN/AView Earnings Details
8/10/2015Q2($0.23)($0.21)ViewN/AView Earnings Details
5/11/2015Q115($0.20)($0.22)ViewN/AView Earnings Details
3/18/2015($0.17)($0.18)ViewN/AView Earnings Details
11/10/2014Q314($0.27)($0.17)ViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)ViewN/AView Earnings Details
5/13/2014Q114($0.20)($0.27)ViewN/AView Earnings Details
3/21/2014($0.18)($0.15)ViewN/AView Earnings Details
11/12/2013Q3($0.18)($0.22)ViewN/AView Earnings Details
8/14/2013Q213($0.19)($0.18)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.18)($0.22)ViewN/AView Earnings Details
11/9/2012Q312($0.18)($0.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Galectin Therapeutics (NASDAQ:GALT)
Current Year EPS Consensus Estimate: $-0.91 EPS
Next Year EPS Consensus Estimate: $-0.28 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.22)($0.22)($0.22)
Q2 20162($0.24)($0.22)($0.23)
Q3 20162($0.20)($0.20)($0.20)
Q4 20162($0.20)($0.20)($0.20)
Q1 20171($0.15)($0.15)($0.15)
Q2 20171($0.16)($0.16)($0.16)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Galectin Therapeutics (NASDAQ:GALT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galectin Therapeutics (NASDAQ:GALT)
Insider Ownership Percentage: 40.30%
Institutional Ownership Percentage: 11.69%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/5/2016Arthur GreenbergDirectorBuy1,666$1.72$2,865.52View SEC Filing  
8/12/2015Peter G TraberCEOBuy2,000$2.00$4,000.00View SEC Filing  
6/1/2015Kevin D FreemanDirectorBuy2,083$2.70$5,624.10View SEC Filing  
6/1/2015Peter G TraberCEOBuy4,000$2.53$10,120.00View SEC Filing  
8/19/2014Arthur GreenbergDirectorBuy1,000$4.56$4,560.00View SEC Filing  
8/15/2014Kevin D FreemanDirectorBuy1,000$4.70$4,700.00View SEC Filing  
8/14/2014Jack W CallicuttCFOBuy1,000$4.55$4,550.00View SEC Filing  
8/14/2014Peter G TraberCEOBuy4,000$4.46$17,840.00View SEC Filing  
8/13/2014Peter G TraberCEOBuy1,000$4.42$4,420.00View SEC Filing  
4/11/2014Steven PrelackDirectorSell6,000$11.84$71,040.00View SEC Filing  
1/13/2014James C CzirrChairmanSell100,000$14.84$1,484,000.00View SEC Filing  
12/4/2013Marc RubinDirectorBuy3,000$8.69$26,070.00View SEC Filing  
11/19/2013Arthur GreenbergDirectorBuy2,000$6.55$13,100.00View SEC Filing  
11/19/2013Peter G TraberCEOBuy1,000$5.53$5,530.00View SEC Filing  
11/18/2013Peter G TraberCEOBuy1,000$5.80$5,800.00View SEC Filing  
11/15/2013James C CzirrChairmanBuy1,000$6.90$6,900.00View SEC Filing  
6/3/2013John F MauldinDirectorBuy1,176$4.21$4,950.96View SEC Filing  
5/28/2013Kevin D FreemanDirectorBuy1,000$4.21$4,210.00View SEC Filing  
10/12/2012Peter G TraberCEOBuy2,500$2.11$5,275.00View SEC Filing  
10/9/2012Peter G TraberCEOBuy2,500$2.00$5,000.00View SEC Filing  
10/8/2012Peter G TraberCEOBuy5,000$2.07$10,350.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Galectin Therapeutics (NASDAQ:GALT)
DateHeadline
benzinga.com logo12 Biggest Mid-Day Losers For Wednesday - Benzinga (NASDAQ:GALT)
www.benzinga.com - September 30 at 5:26 PM
4-traders.com logoGalectin Therapeutics : GALT) is “One to Watch” (NASDAQ:GALT)
www.4-traders.com - September 30 at 10:13 AM
News IconGalectin Therapeutics, Inc. (GALT) is “One to Watch” (NASDAQ:GALT)
missionir.com - September 30 at 10:13 AM
schaeffersresearch.com logoBuzz Stocks: BlackBerry Ltd, Tempur Sealy International Inc, and Galectin Therapeutics Inc - Schaeffers Research (blog) (NASDAQ:GALT)
www.schaeffersresearch.com - September 29 at 5:01 PM
News IconGalectin Therapeutics Inc. (GALT) Updated Broker Price Targets - The De Soto Edge (NASDAQ:GALT)
desotoedge.com - September 29 at 5:01 PM
News IconGalectin Therapeutics, Inc.'s (GALT): Trendy Stock of Yesterday - Hot Stocks Point (NASDAQ:GALT)
www.hotstockspoint.com - September 29 at 5:01 PM
benzinga.com logoWhy Galectin Therapeutics Just Lost Nearly Half Its Market Cap - Benzinga (NASDAQ:GALT)
www.benzinga.com - September 29 at 5:01 PM
investopedia.com logoGalectin Tanks on Failure of NASH Treatment (GALT) (NASDAQ:GALT)
www.investopedia.com - September 29 at 5:01 PM
News IconGalectin Therapeutics Fails Phase 2 Study (NASDAQ:GALT)
www.financialbuzz.com - September 29 at 10:08 AM
finance.yahoo.com logoGalectin Therapeutics downgraded by H.C. Wainwright (NASDAQ:GALT)
finance.yahoo.com - September 29 at 10:08 AM
streetinsider.com logoPre-Open Stock Movers 09/28: (SEED) (AVXL) (ATHX) Higher; (GALT) (TPX) (SONC) Lower (more...) (NASDAQ:GALT)
www.streetinsider.com - September 28 at 4:57 PM
baystreet.ca logoGalectin Therapeutics (GALT) Tumbles on Failing to Meet Endpoints (NASDAQ:GALT)
www.baystreet.ca - September 28 at 4:57 PM
schaeffersresearch.com logoBuzz Stocks: BlackBerry Ltd, Tempur Sealy International Inc, and Galectin Therapeutics Inc (NASDAQ:GALT)
www.schaeffersresearch.com - September 28 at 4:57 PM
thestreet.com logoGalectin Therapeutics (GALT) Stock Declines on Drug Failure, Rating Cut (NASDAQ:GALT)
www.thestreet.com - September 28 at 4:57 PM
streetinsider.com logoGalectin (GALT) Reports Exploratory Phase 2a Pilot Trial of GR-MD-02 in Nash Misses Primary Biomarker Endpoint; Announces $1.5M Private Placement (NASDAQ:GALT)
www.streetinsider.com - September 27 at 5:08 PM
publicnow.com logoGalectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis (NASDAQ:GALT)
www.publicnow.com - September 27 at 5:08 PM
News IconNoteworthy Analyst Ratings of Two Stocks Bonanza Creek Energy Inc (NYSE:BCEI), Galectin Therapeutics Inc ... - The Voice Registrar (NASDAQ:GALT)
voiceregistrar.com - September 27 at 9:45 AM
seekingalpha.com logoA Major Catalyst Awaits Galectin Therapeutics Next Week - Seeking Alpha (NASDAQ:GALT)
seekingalpha.com - September 25 at 4:42 PM
marketexclusive.com logoTwo Speculative NASH Allocations Post Allergan plc Ordinary Shares (NYSE:AGN)’s Tobira Therapeutics Inc (NASDAQ:TBRA) Buyout (NASDAQ:GALT)
marketexclusive.com - September 23 at 4:53 PM
finance.yahoo.com logoCan The Uptrend Continue for Galectin Therapeutics (GALT)? (NASDAQ:GALT)
finance.yahoo.com - September 23 at 4:53 PM
News IconUnder the Microscope, Zeroing in at Galectin Therapeutics, Inc. (NASDAQ:GALT) - Duncan Research (NASDAQ:GALT)
www.duncanindependent.com - September 23 at 10:08 AM
News IconHC Stocks Newsbeat! Galectin Therapeutics Inc (GALT), Clovis Oncology Inc (NASDAQ:CLVS) - share market updates (press release) (NASDAQ:GALT)
sharemarketupdates.com - September 23 at 10:08 AM
News IconAllergan pays $50 mln to buy privately-held Akarna Therapeutics (NASDAQ:GALT)
thelakeandeswave.com - September 22 at 5:14 PM
News IconPenny Stock Investors Keen on Shares of Galectin Therapeutics, Inc. (NASDAQ:GALT) - Duncan Research (NASDAQ:GALT)
www.duncanindependent.com - September 22 at 10:43 AM
benzinga.com logo15 Biggest Mid-Day Gainers For Wednesday - Benzinga (NASDAQ:GALT)
www.benzinga.com - September 22 at 10:43 AM
News IconWhat to do when a water resistant iPhone 7 gets wet (NASDAQ:GALT)
10thousandcouples.com - September 21 at 5:38 PM
bloomberg.com logoAllergan Buys Liver Drug Maker Tobira for Up to $1.7 Billion (NASDAQ:GALT)
www.bloomberg.com - September 21 at 5:38 PM
bloomberg.com logoAllergan Buys Two Liver Disease Companies in Less Than a Day (NASDAQ:GALT)
washpost.bloomberg.com - September 21 at 5:38 PM
investing.com logoU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.90% (NASDAQ:GALT)
www.investing.com - September 21 at 5:38 PM
thecountrycaller.com logoGalectin Therapeutics Inc (GALT) Is A Better NASH Player Than Allergan plc Ordinary Shares (AGN) (NASDAQ:GALT)
www.thecountrycaller.com - September 21 at 5:38 PM
News IconPenny Stock Investors Take an Interest in Galectin Therapeutics, Inc. (NASDAQ:GALT) - Duncan Research (NASDAQ:GALT)
www.duncanindependent.com - September 21 at 9:23 AM
thecountrycaller.com logoGalectin Therapeutics Inc (GALT) Is A Better NASH Player Than Allergan plc Ordinary Shares (AGN) - TCC (NASDAQ:GALT)
www.thecountrycaller.com - September 21 at 9:23 AM
News IconKeen Investors Seek Information on Galectin Therapeutics, Inc. (NASDAQ:GALT) - Duncan Research (NASDAQ:GALT)
www.duncanindependent.com - September 17 at 9:48 AM
News IconStock Update, a Closer Look at Galectin Therapeutics, Inc. (NASDAQ:GALT) - Duncan Research (NASDAQ:GALT)
www.duncanindependent.com - September 15 at 5:30 PM
News IconKeen Investors Narrowing Their Focus on Galectin Therapeutics, Inc. (NASDAQ:GALT) - Duncan Research (NASDAQ:GALT)
www.duncanindependent.com - September 15 at 8:11 AM
News IconGalectin Therapeutics Inc. (NASDAQ: GALT) Stock Rating Reiterated at FBR & Co - BNB Daily (blog) (NASDAQ:GALT)
www.baseball-news-blog.com - August 29 at 9:45 AM
investors.com logoPsoriasis improvement not sufficient to continue says Galectin (NASDAQ:GALT)
www.proactiveinvestors.com - August 25 at 5:09 PM
4-traders.com logoGALECTIN THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (NASDAQ:GALT)
www.4-traders.com - August 25 at 10:09 AM
publicnow.com logoGalectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial (NASDAQ:GALT)
www.publicnow.com - August 25 at 10:09 AM
investornewswire.com logoWill Galectin Therapeutics Inc. (NASDAQ:GALT) Hit $12 Price Target? - Investor Newswire (NASDAQ:GALT)
www.investornewswire.com - August 20 at 9:21 AM
News IconGlobal NASH Market to Exhibit Remarkable 25.56% CAGR between 2020 and 2030 (NASDAQ:GALT)
reports.pr-inside.com - August 19 at 8:04 AM
finance.yahoo.com logoGALECTIN THERAPEUTICS INC Financials (NASDAQ:GALT)
finance.yahoo.com - August 17 at 5:23 PM
News IconStock Update on Galectin Therapeutics, Inc. (NASDAQ:GALT) - Duncan Research (NASDAQ:GALT)
www.duncanindependent.com - August 12 at 8:09 AM
News IconGalectin Reports Second Quarter 2016 Financial Results And Provides Business Update (NASDAQ:GALT)
www.biospace.com - August 9 at 3:53 PM
reuters.com logoBRIEF-Galectin Therapeutics quarterly loss per share $0.20 (NASDAQ:GALT)
www.reuters.com - August 9 at 3:53 PM
streetinsider.com logoForm 8-K GALECTIN THERAPEUTICS For: Aug 09 (NASDAQ:GALT)
www.streetinsider.com - August 9 at 3:53 PM
twst.com logoGalectin Therapeutics Inc.: Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:GALT)
www.twst.com - August 9 at 3:53 PM
biz.yahoo.com logoGALECTIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:GALT)
biz.yahoo.com - August 9 at 8:04 AM
biz.yahoo.com logoGALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:GALT)
biz.yahoo.com - August 9 at 8:04 AM
finance.yahoo.com logoGalectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:GALT)
finance.yahoo.com - August 9 at 8:04 AM

Social

Galectin Therapeutics (NASDAQ:GALT) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff